Research Article

A fractional mathematical model approach on glioblastoma growth: tumor visibility timing and patient survival

Volume: 4 Number: 1 March 31, 2024
EN

A fractional mathematical model approach on glioblastoma growth: tumor visibility timing and patient survival

Abstract

In this paper, we introduce a mathematical model given by \begin{equation} { }^c \mathfrak{D}_t^\alpha u = \nabla \cdot \mathrm{D} \nabla u + \rho f(u) \quad \text{in } \Omega, \end{equation} where $f(u)=\frac{1}{1-u/\mathrm{K}}, \, u/\mathrm{K} \neq 1, \, \mathrm{K} > 0$, to enhance established mathematical methodologies for better understanding glioblastoma dynamics at the macroscopic scale. The tumor growth model exhibits an innovative structure even within the conventional framework, including a proliferation term, $f(u)$, presented in a different form compared to existing macroscopic glioblastoma models. Moreover, it represents a further refined model by incorporating a calibration criterion based on the integration of a fractional derivative, $\alpha$, which differs from the existing models for glioblastoma. Throughout this study, we initially discuss the modeling dynamics of the tumor growth model. Given the frequent recurrence observed in glioblastoma cases, we then track tumor mass formation and provide predictions for tumor visibility timing on medical imaging to elucidate the recurrence periods. Furthermore, we investigate the correlation between tumor growth speed and survival duration to uncover the relationship between these two variables through an experimental approach. To conduct these patient-specific analyses, we employ glioblastoma patient data and present the results via numerical simulations. In conclusion, the findings on tumor visibility timing align with empirical observations, and the investigations into patient survival further corroborate the well-established inter-patient variability for glioblastoma cases.

Keywords

Glioblastoma, Tumor visibility, Survival, Fractional mathematical model, recurrence

Supporting Institution

Scientific and Technological Research Council of Turkiye (TUBITAK)

Project Number

E-21514107-115.99-301087

References

  1. [1] Yabo, Y.A., Niclou, S.P. and Golebiewska, A. Cancer cell heterogeneity and plasticity: a paradigm shift in glioblastoma. Neuro-Oncology, 24(5), 669-682, (2022).
  2. [2] Louis, D.N., Perry, A., Wesseling, P., Brat, D.J., Cree, I.A., Figarella-Branger, D. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-Oncology, 23(8), 1231-1251, (2021).
  3. [3] Carlsson, S.K., Brothers, S.P. and Wahlestedt, C. Emerging treatment strategies for glioblastoma multiforme. EMBO Molecular Medicine, 6(11), 1359-1370, (2014).
  4. [4] Kelley, P.J. and Hunt, C. The limited value of cytoreductive surgery in elderly patients with malignant gliomas. Neurosurgery, 34(1), 62-67, (1994).
  5. [5] Piroth, M.D., Pinkawa, M., Holy, R., Klotz, J., Schaar, S., Stoffels, G. et al. Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. Strahlentherapie und Onkologie, 188(4), 334-339, (2012).
  6. [6] Silbergeld, D.L. and Chicoine, M.R. Isolation and characterization of human malignant glioma cells from histologically normal brain. Journal of Neurosurgery, 86(3), 525-531, (1997).
  7. [7] Harpold, H.L.P., Alvord Jr, E.C. and Swanson, K.R. The evolution of mathematical modeling of glioma proliferation and invasion. Journal of Neuropathology & Experimental Neurology, 66(1), 1-9, (2007).
  8. [8] Pandya, N.M., Dhalla, N.S. and Santani, D.D. Angiogenesis-a new target for future therapy. Vascular Pharmacology, 44(5), 265-274, (2006).
  9. [9] Das, S. Functional Fractional Calculus for System Identification and Controls. Springer: New York, (2008).
  10. [10] Curtin, L., Whitmire, P., White, H., Bond, K.M., Mrugala, M.M., Hu, L.S. et al. Shape matters: morphological metrics of glioblastoma imaging abnormalities as biomarkers of prognosis. Scientific Reports, 11(1), 23202, (2021).
APA
Kar, N., & Özalp, N. (2024). A fractional mathematical model approach on glioblastoma growth: tumor visibility timing and patient survival. Mathematical Modelling and Numerical Simulation With Applications, 4(1), 66-85. https://doi.org/10.53391/mmnsa.1438916
AMA
1.Kar N, Özalp N. A fractional mathematical model approach on glioblastoma growth: tumor visibility timing and patient survival. MMNSA. 2024;4(1):66-85. doi:10.53391/mmnsa.1438916
Chicago
Kar, Nurdan, and Nuri Özalp. 2024. “A Fractional Mathematical Model Approach on Glioblastoma Growth: Tumor Visibility Timing and Patient Survival”. Mathematical Modelling and Numerical Simulation With Applications 4 (1): 66-85. https://doi.org/10.53391/mmnsa.1438916.
EndNote
Kar N, Özalp N (March 1, 2024) A fractional mathematical model approach on glioblastoma growth: tumor visibility timing and patient survival. Mathematical Modelling and Numerical Simulation with Applications 4 1 66–85.
IEEE
[1]N. Kar and N. Özalp, “A fractional mathematical model approach on glioblastoma growth: tumor visibility timing and patient survival”, MMNSA, vol. 4, no. 1, pp. 66–85, Mar. 2024, doi: 10.53391/mmnsa.1438916.
ISNAD
Kar, Nurdan - Özalp, Nuri. “A Fractional Mathematical Model Approach on Glioblastoma Growth: Tumor Visibility Timing and Patient Survival”. Mathematical Modelling and Numerical Simulation with Applications 4/1 (March 1, 2024): 66-85. https://doi.org/10.53391/mmnsa.1438916.
JAMA
1.Kar N, Özalp N. A fractional mathematical model approach on glioblastoma growth: tumor visibility timing and patient survival. MMNSA. 2024;4:66–85.
MLA
Kar, Nurdan, and Nuri Özalp. “A Fractional Mathematical Model Approach on Glioblastoma Growth: Tumor Visibility Timing and Patient Survival”. Mathematical Modelling and Numerical Simulation With Applications, vol. 4, no. 1, Mar. 2024, pp. 66-85, doi:10.53391/mmnsa.1438916.
Vancouver
1.Nurdan Kar, Nuri Özalp. A fractional mathematical model approach on glioblastoma growth: tumor visibility timing and patient survival. MMNSA. 2024 Mar. 1;4(1):66-85. doi:10.53391/mmnsa.1438916